Gray Matter Solutions (GMS) is a pioneering cognitive health technology company committed to transforming the early detection and prevention of dementia through advanced digital neuro-assessment, AI-driven analytics, and personalized brain health interventions. Founded with the vision of enabling proactive brain health for every individual, GMS develops clinically validated, accessible, and scalable tools that empower healthcare providers to identify cognitive decline at its earliest and most treatable stages.

Since its inception, GMS has been dedicated to bridging the global gap in cerebrovascular and cognitive impairment detection—especially Vascular Cognitive Impairment (VCI), one of Asia’s most prevalent yet underdiagnosed causes of dementia. Its flagship solutions, ReCOGnAIze and RevitalAIze, combine neuroscience, machine learning, gamified assessment, and digital therapeutics to deliver precise cognitive insights and personalized interventions across clinics, communities, and population health programs.

GMS’s growing pipeline includes next-generation biomarkers, digital phenotyping frameworks, and AI-integrated risk scores that serve as scalable proxies for biological disease activity. With a multidisciplinary team of neuroscientists, clinicians, engineers, and digital health innovators, GMS is driven by the mission to make a meaningful impact on patients, families, and societies across Asia and beyond.

Aligned with global priorities such as the United Nations Sustainable Development Goals and the World Bank/IFC Ethical Principles in Health Care (EPiHC), GMS is committed to delivering equitable, ethical, and high-quality cognitive health technologies that shape the future of preventive neurology.

VISIT WEBSITE